Market closedADR
Opthea/$OPT
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Opthea
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.
Ticker
$OPT
Sector
Trading on
Industry
Biotechnology
Headquarters
South Yarra, Australia
Employees
-
Website
Opthea Metrics
BasicAdvanced
$664M
Market cap
-
P/E ratio
-$0.35
EPS
1.61
Beta
-
Dividend rate
Price and volume
Market cap
$664M
Beta
1.61
52-week high
$4.98
52-week low
$1.63
Average daily volume
35K
Financial strength
Current ratio
2.938
Quick ratio
2.877
Long term debt to equity
-264.524
Total debt to equity
-264.647
Interest coverage (TTM)
-6.34%
Management effectiveness
Return on assets (TTM)
-83.43%
Return on equity (TTM)
539.39%
Valuation
Price to revenue (TTM)
10,185.366
Price to book
-11.73
Price to tangible book (TTM)
-11.73
Price to free cash flow (TTM)
-16.549
Growth
Revenue change (TTM)
-32.03%
Earnings per share change (TTM)
7.17%
3-year revenue growth (CAGR)
39.93%
3-year earnings per share growth (CAGR)
34.60%
What the Analysts think about Opthea
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Opthea stock.
Opthea Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Opthea Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Opthea News
AllArticlesVideos
Opthea Wet AMD Program to be Presented at Innovate Retina
GlobeNewsWire·4 weeks ago
Opthea to Participate in the UBS Virtual Ophthalmology Day 2024
GlobeNewsWire·1 month ago
Opthea Announces Completion of Drug Substance PPQ Campaign Validating Manufacturing Process of Sozinibercept
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Opthea stock?
Opthea (OPT) has a market cap of $664M as of November 08, 2024.
What is the P/E ratio for Opthea stock?
The price to earnings (P/E) ratio for Opthea (OPT) stock is 0 as of November 08, 2024.
Does Opthea stock pay dividends?
No, Opthea (OPT) stock does not pay dividends to its shareholders as of November 08, 2024.
When is the next Opthea dividend payment date?
Opthea (OPT) stock does not pay dividends to its shareholders.
What is the beta indicator for Opthea?
Opthea (OPT) has a beta rating of 1.61. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.